Ulpiano Jiménez

6.1k total citations
12 papers, 334 citations indexed

About

Ulpiano Jiménez is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Ulpiano Jiménez has authored 12 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Ulpiano Jiménez's work include Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Cancer Genomics and Diagnostics (4 papers). Ulpiano Jiménez is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Cancer Genomics and Diagnostics (4 papers). Ulpiano Jiménez collaborates with scholars based in Spain and United States. Ulpiano Jiménez's co-authors include J.L. González-Larriba, Carlos Camps, Rafael Rosell, Dolores Isla, José Javier Sánchez, R. de las Peñas, Mariano Provencio, Bartomeu Massutí, Ana Ruiz‐Casado and Pilar Díz and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Journal of Thoracic Oncology.

In The Last Decade

Ulpiano Jiménez

12 papers receiving 326 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ulpiano Jiménez Spain 6 281 236 86 61 30 12 334
Diana Gernhardt United States 7 200 0.7× 248 1.1× 135 1.6× 56 0.9× 22 0.7× 8 338
B.C. Cho South Korea 8 232 0.8× 204 0.9× 90 1.0× 47 0.8× 27 0.9× 33 280
Ignacio Tusquets Spain 9 110 0.4× 131 0.6× 50 0.6× 59 1.0× 43 1.4× 16 252
E‐E Ke China 8 239 0.9× 200 0.8× 80 0.9× 51 0.8× 32 1.1× 12 315
Y. Y. Janjigian United States 9 293 1.0× 246 1.0× 98 1.1× 31 0.5× 41 1.4× 29 330
Maarten Neerincx Netherlands 7 89 0.3× 151 0.6× 106 1.2× 84 1.4× 50 1.7× 12 284
Ana León Spain 9 70 0.2× 196 0.8× 72 0.8× 101 1.7× 45 1.5× 23 260
Edit Csada Hungary 7 280 1.0× 249 1.1× 153 1.8× 53 0.9× 17 0.6× 9 380
Matthew Labriola United States 6 159 0.6× 137 0.6× 72 0.8× 82 1.3× 28 0.9× 23 238
Sara Fancelli Italy 9 134 0.5× 197 0.8× 103 1.2× 58 1.0× 26 0.9× 25 302

Countries citing papers authored by Ulpiano Jiménez

Since Specialization
Citations

This map shows the geographic impact of Ulpiano Jiménez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulpiano Jiménez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulpiano Jiménez more than expected).

Fields of papers citing papers by Ulpiano Jiménez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulpiano Jiménez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulpiano Jiménez. The network helps show where Ulpiano Jiménez may publish in the future.

Co-authorship network of co-authors of Ulpiano Jiménez

This figure shows the co-authorship network connecting the top 25 collaborators of Ulpiano Jiménez. A scholar is included among the top collaborators of Ulpiano Jiménez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulpiano Jiménez. Ulpiano Jiménez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Provencio, Mariano, Carlos Camps, Manuel Cobo, et al.. (2012). Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. Cancer Chemotherapy and Pharmacology. 70(6). 883–890. 17 indexed citations
2.
Sánchez, José Miguel, Manuel Cobo, Bartomeu Massutí, et al.. (2012). Pilot SCAT trial: Spanish customized adjuvant chemotherapy (CT) based on BRCA1 mRNA expression levels (l) in resected stage II-IIIA non-small cell lung cancer (NSCLC) patients (p).. Journal of Clinical Oncology. 30(15_suppl). 7011–7011. 5 indexed citations
3.
Massutí, Bartomeu, Ulpiano Jiménez, J.M. Rodríguez Paniagua, et al.. (2011). SCAT trial: Phase III Spanish customized adjuvant treatment according BRCA1 mRNA levels in stage II-IIIA non-small cell lung cancer.. Journal of Clinical Oncology. 29(15_suppl). TPS208–TPS208. 1 indexed citations
4.
Grávalos, Cristina, Carlos Gómez-Martín, Fernando Rivera, et al.. (2011). Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clinical & Translational Oncology. 13(3). 179–184. 60 indexed citations
5.
Simonetti, S., Miguel Ángel Molina‐Vila, Cristina Queralt, et al.. (2010). Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. Journal of Translational Medicine. 8(1). 135–135. 76 indexed citations
6.
Cobo, M., Bartomeu Massutí, Teresa Morán, et al.. (2008). Spanish customized adjuvant trial (SCAT) based on BRCA1 mRNA levels. Journal of Clinical Oncology. 26(15_suppl). 7533–7533. 17 indexed citations
7.
Isla, Dolores, et al.. (2007). P3-095: Erlotinib in advanced squamous cell carcinoma of the lung. Journal of Thoracic Oncology. 2(8). S719–S719. 1 indexed citations
8.
Morán, María Teresa Cabero, Dolores Isla, Manuel Cobo, et al.. (2007). PD2-3-3: High correspondence between EGFR mutations in tissue and in circulating DNA form non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS). Journal of Thoracic Oncology. 2(8). S444–S444. 1 indexed citations
9.
Jiménez, Ulpiano, Alfonso Gúrpide, Dolores Isla, et al.. (2007). Erlotinib for first line treatment in unselected patients (p) with advanced or metastatic non-small cell lung carcinoma (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 7639–7639. 3 indexed citations
10.
Alberola, V., Carlos Camps, Mariano Provencio, et al.. (2003). Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non–Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial. Journal of Clinical Oncology. 21(17). 3207–3213. 148 indexed citations
11.
12.
Zapatero, A., C. Martín de Vidales, Ulpiano Jiménez, et al.. (1995). 1166 Prospective trial of chemotherapy and radiotherapy for invasive bladder carcinoma: Preliminary results. European Journal of Cancer. 31. S244–S244. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Diana Gernhardt Breakdown of academic impact, for papers by B.C. Cho Breakdown of academic impact, for papers by Ignacio Tusquets Breakdown of academic impact, for papers by E‐E Ke Breakdown of academic impact, for papers by Y. Y. Janjigian Breakdown of academic impact, for papers by Maarten Neerincx Breakdown of academic impact, for papers by Ana León Breakdown of academic impact, for papers by Edit Csada Breakdown of academic impact, for papers by Matthew Labriola Breakdown of academic impact, for papers by Sara Fancelli
Rankless by CCL
2026